Dr. Neil Bressler, chair of the Diabetic Retinopathy Clinical Research Network (DRCR.net), discusses this year’s breakthrough accomplishment from the network--a study involving 52 sites that showed ranibizumab in combination with laser is superior to laser alone in treating diabetic macular edema. Dr. Bressler expects this development to save hundreds of thousands of patients from vision loss.

Financial Disclosures: Dr. Bressler receives grant support from Abbott Medical Optics, Allergan, Inc., Bausch & Lomb Surgical, Carl Zeiss Meditec, EMMES Corporation, ForSight Labs, LLC, Genentech, Lumenis, Inc., Notal Vision, Ltd., Novartis Pharmaceuticals Corporation, Othera Pharmaceuticals, Inc., QLT Phototherapeutics, Inc., Regeneron, and Steba Biotech. Dr. Kim is a consultant for and receives grant support from Allergan and Genentech. She also receives grant support from the National Eye Institute and Regeneron as a clinical trial investigator.